Synthetic consortia of nanobody-coupled and formatted bacteria for prophylaxis and therapy interventions targeting microbiome dysbiosis-associated diseases and co-morbidities

Kenneth Timmis; James Kenneth Timmis; Harald Brüssow; Luis Ángel Fernández

doi:10.1111/1751-7915.13355

Synthetic consortia of nanobody-coupled and formatted bacteria for prophylaxis and therapy interventions targeting microbiome dysbiosis-associated diseases and co-morbidities

Kenneth Timmis^*, James Kenneth Timmis, Harald Brüssow, Luis Ángel Fernández

^*Corresponding author for this work

Athena Institute

Research output: Contribution to Journal › Article › Academic › peer-review

Abstract

Designed nanobody‐linked synthetic consortia for microbiota dysbiosis therapies. A. Nanobodies (Nb) are selected for specific antigens on target bacteria destined for a synthetic therapy consortium that may consist of two (B) or multiple (C) members. For the treatment of dysbiosis co‐morbidities requiring two functionally distinct consortia, these may be linked through a common member to generate a single bi‐functional microbiota therapy (D). [image]

Original language	English
Pages (from-to)	58-65
Number of pages	8
Journal	Microbial Biotechnology
Volume	12
Issue number	1
Early online date	21 Dec 2018
DOIs	https://doi.org/10.1111/1751-7915.13355
Publication status	Published - Jan 2019

Funding

KT expresses infinite gratitude to Victor de Lorenzo for many things, but especially for first sharing in 2003/4 the idea of precise design of synthetic bacterial consortia by means of camel nanobodies that specifically, physically and stably link consortium partners, subsequently published in 2008 (de Lorenzo, 2008), which triggered the idea of this Crystal Ball article. Work in the lab of LAF is supported by the Grants BIO2017-89081-R (Agencia Española de Investigacion AEI/MICIU/FEDER, EU), ERC-2012-ADG_20120314 (European Research Council, EU), LCCM_P59474 (Wellcome Trust, UK), and Syn-Logic-CSIC contract 20182256. No conflicts of interests are declared.

Funders	Funder number
Agencia Española de Investigacion AEI/MICIU/FEDER
Wellcome Trust	20182256
European Commission	ERC-2012-ADG_20120314
European Research Council	LCCM_P59474

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/1751-7915.13355

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302794

Persistent URL (handle)

Persistent link

Cite this

@article{46d78653f66f4cab9dd5c9668a13c41f,

title = "Synthetic consortia of nanobody-coupled and formatted bacteria for prophylaxis and therapy interventions targeting microbiome dysbiosis-associated diseases and co-morbidities",

abstract = "Designed nanobody‐linked synthetic consortia for microbiota dysbiosis therapies. A. Nanobodies (Nb) are selected for specific antigens on target bacteria destined for a synthetic therapy consortium that may consist of two (B) or multiple (C) members. For the treatment of dysbiosis co‐morbidities requiring two functionally distinct consortia, these may be linked through a common member to generate a single bi‐functional microbiota therapy (D). [image]",

author = "Kenneth Timmis and Timmis, {James Kenneth} and Harald Br{\"u}ssow and Fern{\'a}ndez, {Luis {\'A}ngel}",

year = "2019",

month = jan,

doi = "10.1111/1751-7915.13355",

language = "English",

volume = "12",

pages = "58--65",

journal = "Microbial Biotechnology",

issn = "1751-7907",

publisher = "Wiley",

number = "1",

}

Synthetic consortia of nanobody-coupled and formatted bacteria for prophylaxis and therapy interventions targeting microbiome dysbiosis-associated diseases and co-morbidities. / Timmis, Kenneth; Timmis, James Kenneth; Brüssow, Harald et al.
In: Microbial Biotechnology, Vol. 12, No. 1, 01.2019, p. 58-65.

Research output: Contribution to Journal › Article › Academic › peer-review

TY - JOUR

T1 - Synthetic consortia of nanobody-coupled and formatted bacteria for prophylaxis and therapy interventions targeting microbiome dysbiosis-associated diseases and co-morbidities

AU - Timmis, Kenneth

AU - Timmis, James Kenneth

AU - Brüssow, Harald

AU - Fernández, Luis Ángel

PY - 2019/1

Y1 - 2019/1

N2 - Designed nanobody‐linked synthetic consortia for microbiota dysbiosis therapies. A. Nanobodies (Nb) are selected for specific antigens on target bacteria destined for a synthetic therapy consortium that may consist of two (B) or multiple (C) members. For the treatment of dysbiosis co‐morbidities requiring two functionally distinct consortia, these may be linked through a common member to generate a single bi‐functional microbiota therapy (D). [image]

AB - Designed nanobody‐linked synthetic consortia for microbiota dysbiosis therapies. A. Nanobodies (Nb) are selected for specific antigens on target bacteria destined for a synthetic therapy consortium that may consist of two (B) or multiple (C) members. For the treatment of dysbiosis co‐morbidities requiring two functionally distinct consortia, these may be linked through a common member to generate a single bi‐functional microbiota therapy (D). [image]

UR - http://www.scopus.com/inward/record.url?scp=85058899315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058899315&partnerID=8YFLogxK

U2 - 10.1111/1751-7915.13355

DO - 10.1111/1751-7915.13355

M3 - Article

C2 - 30575298

AN - SCOPUS:85058899315

SN - 1751-7907

VL - 12

SP - 58

EP - 65

JO - Microbial Biotechnology

JF - Microbial Biotechnology

IS - 1

ER -

Synthetic consortia of nanobody-coupled and formatted bacteria for prophylaxis and therapy interventions targeting microbiome dysbiosis-associated diseases and co-morbidities

Abstract

Funding

UN SDGs

Access to Document

Persistent URL (handle)

Other files and links

Fingerprint

Cite this